keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall lung cancer

keyword
https://www.readbyqxmd.com/read/28081338/new-immunohistochemical-markers-in-the-differential-diagnosisof-nonsmall-cell-lung-carcinoma
#1
Ferda Bir, Duygu Çeliker, Binnaz Fatma Evyapan, Arzu Yaren, Tamer Edirne
BACKGROUND/AIM: The aim of this study was to investigate Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in the differential diagnosis and prognosis of nonsmall cell lung cancer. MATERIALS AND METHODS: The expression of Napsin-A, NTRK-1, NTRK-2, and Desmoglein-3 was examined by immunohistochemistry in 50 squamous cell carcinomas and 50 adenocarcinomas. Desmocollin-3 was investigated in 29 squamous cell carcinoma and 29 adenocarcinoma cases. Associations between expression profiles of Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in lung cancers and clinicopathological variables were analyzed...
December 20, 2016: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28077049/evaluation-on-biological-compatibility-of-carboxymethyl-chitosan-as-biomaterials-for-antitumor-drug-delivery
#2
Zhiwen Jiang, Baoqin Han, Wanshun Liu, Yanfei Peng
Carboxymethyl-chitosan, a water-soluble derivative of chitosan, has emerged as a promising candidate for biomedical applications due to its excellent water solubility, biodegradation, biocompatibility, hydrating, antimicrobial, and nontoxicity. In this paper, the antitumor proliferation and metastasis was studied in vitro and in vivo to evaluate biocompatibility of carboxymethyl-chitosan as biomaterials for antitumor drug delivery. The results showed that carboxymethyl-chitosan could significantly reduce the clone formation and tumor migration of human cancer cells including kidney cancer cell line OS-RC-2, gastric cancer cell line SGC-7901, colon cancer cell line HT-29, and nonsmall cell lung cancer cell line NCI-H1650 in vitro...
January 1, 2017: Journal of Biomaterials Applications
https://www.readbyqxmd.com/read/28059973/long-term-survival-based-on-the-surgical-approach-to-lobectomy-for-clinical-stage-i-nonsmall-cell-lung-cancer-comparison-of-robotic-video-assisted-thoracic-surgery-and-thoracotomy-lobectomy
#3
Hao-Xian Yang, Kaitlin M Woo, Camelia S Sima, Manjit S Bains, Prasad S Adusumilli, James Huang, David J Finley, Nabil P Rizk, Valerie W Rusch, David R Jones, Bernard J Park
OBJECTIVE: To compare the long-term outcomes among robotic, video-assisted thoracic surgery (VATS), and open lobectomy in stage I nonsmall cell lung cancer (NSCLC). BACKGROUND: Survival comparisons between robotic, VATS, and open lobectomy in NSCLC have not yet been reported. Some studies have suggested that survival after VATS is superior, for unclear reasons. METHODS: Three cohorts (robotic, VATS, and open) of clinical stage I NSCLC patients were matched by propensity score and compared to assess overall survival (OS) and disease-free survival (DFS)...
February 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28054538/erratum-evaluation-of-anaplastic-lymphoma-kinase-expression-in-nonsmall-cell-lung-cancer-a-tissue-microarray-analysis
#4
(no author information available yet)
[This corrects the article DOI: 10.4103/0973-1482.170940.].
July 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28053840/no-detection-of-episomal-or-integrated-high-risk-human-papillomavirus-in-nonsmall-cell-lung-carcinomas-among-korean-population
#5
Jeong Eun Lee, Yong-Moon Lee, In-Ock Seong, Min-Woong Kang, Choong Sik Lee, Kyung-Hee Kim
OBJECTIVES: High-risk human papillomavirus (hrHPV) is known to be a representative cancer-causing agent in the genital and head and neck regions. Many studies have detected hrHPV DNA in nonsmall cell lung carcinoma. However, hrHPV-etiologic correlation in nonsmall cell lung carcinoma remains unclear. This study is designed to determine the prevalence of episomal or integrated hrHPV DNA in nonsmall cell lung carcinoma among the Korean population. METHODS: Surgically resected nonsmall cell lung carcinoma tissues, including 134 cases of squamous cell carcinoma (SqCC) and 99 cases of adenocarcinoma (ADC), were examined...
December 2016: Osong Public Health and Research Perspectives
https://www.readbyqxmd.com/read/28049169/management-of-stage-i-and-ii-nonsmall-cell-lung-cancer
#6
Fiona McDonald, Michèle De Waele, Lizza E L Hendriks, Corinne Faivre-Finn, Anne-Marie C Dingemans, Paul E Van Schil
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28043483/outcome-of-patients-with-pn2-potentially-resectable-nonsmall-cell-lung-cancer-who-underwent-surgery-after-induction-chemotherapy
#7
Lorenzo Spaggiari, Monica Casiraghi, Juliana Guarize, Daniela Brambilla, Francesco Petrella, Patrick Maisonneuve, Filippo De Marinis
Patients with stage IIIA-ipsilateral mediastinal lymph node involvement (N2) non-small cell lung cancer (NSCLC) represent a heterogeneous group with different clinical presentation. The aim of this study was to analyze a series of patients with "potentially resectable" stage IIIA-pathologically proven N2 (pN2) NSCLC undergoing induction chemotherapy followed by surgery to evaluate their long-term outcomes and to identify prognostic factors. Out of 287 patients who underwent induction chemotherapy for NSCLC with ipsilateral mediastinal lymph node involvement pathologically proven, we retrospectively evaluated 141 (49%) patients with no clinical evidence of progression after induction chemotherapy and candidates for surgery...
July 2016: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28043482/immune-response-after-radiofrequency-ablation-and-surgical-resection-in-nonsmall-cell-lung-cancer
#8
Thomas Schneider, Hans Hoffmann, Hendrik Dienemann, Ester Herpel, Claus Peter Heussel, Alexander H Enk, Sabine Ring, Karsten Mahnke
The objective includes radiofrequency ablation (RFA) of a cancerous nodule results in immunogenic cell death. Tumor antigens are presented and the inflammatory environment may help stimulate adaptive and innate antitumor immunity. The objective of this study was to investigate the immune response following RFA and subsequent surgical resection in early stage non-small cell lung cancer (NSCLC). In methods, a single-session approach of computed tomography-guided tumor biopsy with immediate frozen section (and proof of NSCLC) was performed followed by RFA of the tumor in 4 patients with a solitary pulmonary nodule...
July 2016: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28039718/video-assisted-thoracoscopic-lobectomy-mitigates-adverse-oncological-effects-of-delayed-adjuvant-chemotherapy-for-nonsmall-cell-lung-cancer-patients
#9
Xiaogang Jing, Ying Lin, Beifeng Zhang, Guojun Zhang
PURPOSE: Delaying adjuvant chemotherapy initiation >8 weeks after radical lobectomy for non-small cell lung cancer (NSCLC) adversely affects overall survival. The effect of video-assisted thoracoscopic lobectomy (VATS) on adjuvant chemotherapy initiation is yet unclear. This study aimed to determine if using VATS for NSCLC resection affected the timing of adjuvant chemotherapy and oncological outcomes. METHODS: Patients who underwent radical lobectomy for pathological stage II or IIIA NSCLC and received adjuvant chemotherapy between January 2009 and January 2016 were identified from a prospectively maintained lung cancer database...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28033287/cyfra-21-1-is-an-early-predictor-of-chemotherapeutic-effectiveness-in-advanced-nonsmall-cell-lung-cancer-an-observational-study
#10
Tongwei Zhao, Ying Jin, Guangyun Mao, Yaping Wei, Guoqing Wu, Xiao Ye, Yonglie Zhou, Guorong Yuan, Liang Gao, Yupeng Hong, Yun Chen, Chaojin Hong, Hongying Zhou, Dan Su, Zhiquan Qin, Liqin Lu
Serum cytokeratin 19 fragment (CYFRA21-1) has been found to be a useful prognostic marker in lung cancer. Previous studies have revealed that change in CYFRA21-1 synchronously predicted therapeutic effectiveness in advanced nonsmall cell lung cancer (NSCLC) after the second cycle of chemotherapy. The objective of this study was to investigate the early predictive value of percentage change in serum CYFRA21-1 from pretreatment to completion of the first cycle of chemotherapy for chemotherapeutic effectiveness in advanced NSCLC patients...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28033249/a-meta-analysis-of-efficacy-and-safety-of-antibodies-targeting-pd-1-pd-l1-in-treatment-of-advanced-nonsmall-cell-lung-cancer
#11
Cuihua Wang, Xuetao Yu, Wei Wang
BACKGROUND: Nonsmall cell lung cancer (NSCLC)-patients treated with standard chemotherapy experienced progression rapidly. A novel therapy based on programed death 1 (PD-1)/programed death ligand 1 (PD-L1) inhibitors showed an increasing potential in several malignancies including advanced NSCLC. OBJECTIVES: This article is a meta-analysis aiming to systematically evaluate the efficacy and safety profiles of PD-1/PD-L1 agents in patients with NSCLC. DATA SOURCES: Data were collected from eligible studies searched from PubMed, ScienceDirect, and Web of Science...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28027103/neoadjuvant-approach-for-nonsmall-cell-lung-cancer-overview-of-the-current-issues
#12
Giulio Francolini, Katia Ferrari, Vieri Scotti
PURPOSE OF REVIEW: Despite the large numbers of studies, role of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy is debated. This approach would increase resectability in locally advanced patients, and improve surgical outcome in resectable patients. Thus, an overview of recent literature is relevant to highlight the current issues. RECENT FINDINGS: Literature in the previous year mainly focused on overall treatment strategy, radiotherapy technique, role of radiological response and metabolic imaging, and biological agents in this setting...
December 23, 2016: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27996367/video-assisted-thoracoscopic-lobectomy-is-the-preferred-approach-following-induction-chemotherapy
#13
Mohamed K Kamel, Abu Nasar, Brendon M Stiles, Nasser K Altorki, Jeffrey L Port
OBJECTIVE: A video-assisted thoracoscopic surgical (VATS) resection, after induction chemotherapy, has long been considered a relative contraindication. We report our experience with VATS lobectomy after induction chemotherapy for patients with nonsmall cell lung cancer (NSCLC), with propensity-matched group of patients, who underwent an open approach, to determine safety and oncological outcome. METHODS: A retrospective review of a prospective database (2002-2014) was performed to identify patients undergoing potentially curative lobectomy for NSCLC after induction therapy...
December 20, 2016: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/27996312/overexpression-of-tspan8-promotes-tumor-cell-viability-and-proliferation-in-nonsmall-cell-lung-cancer
#14
Zheng Dong, Lijiang Zhao, Shijun Lu, Jie Xiong, Zhiguang Geng
BACKGROUND: Overexpression of TSPAN8 has been involved in several epithelial cancers and TSPAN8 can form a complex with a variety of proteins to participate in several import cellular functions. However, the effects of TSPAN8 in nonsmall cell lung cancer (NSCLC) remain unclear. MATERIALS AND METHODS: In this study, the authors determined the expression of TSPAN in several NSCLC cell lines (95C, A549, H1299, and 95D) and human bronchial epithelial (HBE) cells. Furthermore, the authors investigated the biological function of TSPAN8 in NSCLC cell lines using gain-of-function and loss-of-function assays, as well as the underlying mechanisms...
December 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27977598/egfr-tkis-versus-taxanes-agents-in-therapy-for-nonsmall-cell-lung-cancer-patients-a-prisma-compliant-systematic-review-with-meta-analysis-and-meta-regression
#15
Na An, Yingshi Zhang, Huibin Niu, Zuojing Li, Jiayi Cai, Qingchun Zhao, Qing Li
BACKGROUND: Currently, the nonsmall-cell lung cancer (NSCLC) is a worldwide disease, which has very poor influence on life quality, whereas the therapeutic effects of drugs for it are not satisfactory. The aim of our PRISMA-compliant systematic review and meta-analysis was to compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with Taxanes in patients with lung tumors. METHODS: We collected randomized controlled trials (RCTs) of EGFR-TKIs (gefitinib, erlotinib) versus Taxanes (docetaxel, paclitaxel) for the treatment of NSCLC by searching PubMed, EMbase, and the Cochrane library databases until April, 2016...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27966297/the-role-of-apelin-in-the-assessment-of-response-to-chemotherapyand-prognosis-in-stage-4-nonsmall-cell-lung-cancer
#16
Sinem Ermin, Gürsel Çok, Ali Veral, Timur Köse
BACKGROUND/AIM: Prediction of response to chemotherapy and prognosis bears clinical significance in patients with lung cancer. The aim of the study was to examine the association between apelin expression in tumor tissues and overall survival, progression-free survival, chemoresistance, and treatment response in stage 4 nonsmall cell lung cancer (NSCLC) patients undergoing chemotherapy. MATERIALS AND METHODS: A total of 81 patients who received chemotherapy due to a biopsy-documented diagnosis of NSCLC between 2004 and 2011 were retrospectively studied...
November 17, 2016: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/27922540/prognostic-value-of-quantitative-pet-ct-in-patients-with-a-nonsmall-cell-lung-cancer-and-another-primary-cancer
#17
Xuee Zhu, Chuanhong Liao, Bill C Penney, Feng Li, Mark K Ferguson, Cassie A Simon, Tianming Wu, Haiyan Liu, Yonglin Pu
OBJECTIVE: The staging and management of patients with newly diagnosed nonsmall cell lung cancer (NSCLC) in the setting of recently diagnosed other (metachronous or synchronous) primary cancer are challenging. This retrospective cohort study was carried out to test our hypothesis that baseline 2-deoxy-2-[F]fluoro-D-glucose (F-FDG) PET/CT parameters, including whole-body metabolic tumor volume (MTVWB), total lesion glycolysis (TLGWB), and maximum standardized uptake value (SUVmaxWB), are associated with the overall survival (OS) of such patients...
December 2, 2016: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27902583/adverse-events-risk-associated-with-anti-vegfr-agents-in-the-treatment-of-advanced-nonsmall-cell-lung-cancer-a-meta-analysis
#18
Biao Gu, WenChuang Gao, HongJun Chu, Jian Gao, Zhi Fu, Hui Ding, JunJie Lv, QingQuan Wu
To perform this meta-analysis, we investigated the risk of the most clinically relevant adverse events related to antivascular endothelial growth factor receptor (VEGFR) agents in advanced nonsmall-cell lung cancer (NSCLC).A comprehensive literature search for studies published up to October 2015 was performed. Prospective randomized controlled phase II/III clinical trials that comparing therapy with or without anti-VEGFR agents for advanced NSCLC were included for analysis. Summary relative risk (RR) and 95% confidence intervals (CIs) were calculated using random effects or fixed effects according to the heterogeneity among included trials...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27901003/fibroblast-growth-factor-receptor-1-gene-amplification-in-nonsmall-cell-lung-cancer
#19
REVIEW
Jian-Long Miao, Rui-Juan Liu, Jin-Hua Zhou, Shu-Hua Meng
OBJECTIVE: To review the prevalence and prognostic significance of fibroblast growth factor receptor 1 (FGFR1) amplification and to establish an association between FGFR1 amplification and the clinical characteristics of nonsmall cell lung cancer (NSCLC). DATA SOURCES: We searched PubMed for English-language studies published between January 2010 and May 2016. STUDY SELECTION: We included all relevant articles, with no limitation of study design...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27898232/unfolded-protein-response-promotes-doxorubicin-induced-nonsmall-cell-lung-cancer-cells-apoptosis-via-the-mtor-pathway-inhibition
#20
Xiaofang Zhao, Yan Yang, Fuli Yao, Bin Xiao, Ying Cheng, Chunhong Feng, Chunyan Duan, Chunyan Zhang, Youping Liu, Hong Li, Bo Xiao, Rongyang Dai
Drug resistance is extremely common in nonsmall cell lung cancer (NSCLC) and is one of the major problems in NSCLC chemotherapy. However, the detailed mechanisms remain largely unknown. Unfolded protein response (UPR) is involved in the tumorigenesis of NSCLC. Here, the authors demonstrated that the UPR promotes poly (ADP-ribose) polymerase activation (PARP) cleavage in NSCLC cells on doxorubicin treatment, which is a hallmark of apoptosis and caspase activation. In NSCLC cells, doxorubicin treatment triggers the UPR activation, which subsequently promotes doxorubicin-mediated apoptosis...
December 2016: Cancer Biotherapy & Radiopharmaceuticals
keyword
keyword
55784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"